Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Infant deaths during a trial of a medicine that protects against respiratory syncytial virus were caused by unrelated factors ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...